Xilio Development Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $82.69 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Xilio Development Inc had its IPO on 2021-10-22 under the ticker symbol XLO.
The company operates in the Healthcare sector and Biotechnology industry. Xilio Development Inc has a staff strength of 89 employees.
Shares of Xilio Development Inc opened at $2.96 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $2.91 - $3.18, and closed at $3.17.
This is a +7.46% increase from the previous day's closing price.
A total volume of 11,838 shares were traded at the close of the day’s session.
In the last one week, shares of Xilio Development Inc have increased by +6.73%.
Xilio Development Inc's Key Ratios
Xilio Development Inc has a market cap of $82.69 million, indicating a price to book ratio of 0.5177 and a price to sales ratio of 0.
In the last 12-months Xilio Development Inc’s revenue was $0 with a gross profit of $-56774000 and an EBITDA of $-87302000. The EBITDA ratio measures Xilio Development Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xilio Development Inc’s operating margin was 0% while its return on assets stood at -31.2% with a return of equity of -60.62%.
In Q4, Xilio Development Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Xilio Development Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.37 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xilio Development Inc’s profitability.
Xilio Development Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.6405. Its price to sales ratio in the trailing 12-months stood at 0.
Xilio Development Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $139.17 million
- Total Liabilities
- $21.12 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Xilio Development Inc ended 2023 with $139.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $139.17 million while shareholder equity stood at $105.65 million.
Xilio Development Inc ended 2023 with $0 in deferred long-term liabilities, $21.12 million in other current liabilities, 3000.00 in common stock, $-249108000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $120.39 million and cash and short-term investments were $120.39 million. The company’s total short-term debt was $7,585,000 while long-term debt stood at $3.17 million.
Xilio Development Inc’s total current assets stands at $124.50 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $267000.00 compared to accounts payable of $3.13 million and inventory worth $0.
In 2023, Xilio Development Inc's operating cash flow was $0 while its capital expenditure stood at $98000.
Comparatively, Xilio Development Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Xilio Development Inc stock is currently trading at $3.17 per share. It touched a 52-week high of $7.53 and a 52-week low of $7.53. Analysts tracking the stock have a 12-month average target price of $9.75.
Its 50-day moving average was $3.23 and 200-day moving average was $2.75 The short ratio stood at 3.46 indicating a short percent outstanding of 0%.
Around 740.1% of the company’s stock are held by insiders while 6630.5% are held by institutions.
Frequently Asked Questions About Xilio Development Inc
Similar Industry Stocks (Biotechnology)
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.